Compare Endeavour Silver Corp (EXK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs TG Therapeutics Inc — how do they compare? Endeavour Silver Corp trades at $8.67 (market cap $2.54B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 3.2× Endeavour Silver Corp's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and TG Therapeutics Inc for 16 Days on average.
| EXK | TGTX | |
|---|---|---|
Market Cap | $2.54B | $8.16B |
Volume | 7,077,330 | 1,735,121 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $59.06 |
52-Week Low | $7.07 | $26.94 |
Typical Hold Time | 25 Days | 16 Days |
Enterprise Value | $2.54B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.72, up 4.81% today, showing mixed technical signals with bearish moving averages but neutral oscillators. The company demonstrates improving fundamentals with Q1 2026 earnings beating expectations and projected revenue growth from $468M to $737M in 2026. Recent operational developments include Terronera mine resumption and Kolpa expansion, though mechanical issues at Guanacevi mine present near-term challenges.
EXK presents a growth story with strong analyst support (78.57% buy rating) and improving profitability, but faces operational risks and high valuation multiples. The stock's outlook depends on successful mine execution and silver price stability, with technical resistance at $9.00 providing a near-term hurdle for further upside.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
